List of works - Sushmita Sinha

A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS.

scientific article published in November 2007

Altered expression of SIRPγ on the T-cells of relapsing remitting multiple sclerosis and type 1 diabetes patients could potentiate effector responses from T-cells

scientific article published on 27 August 2020

An autoimmune disease risk SNP, rs2281808, in SIRPG is associated with reduced expression of SIRPγ and heightened effector state in human CD8 T-cells

scientific article published in Scientific Reports

Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.

scientific article

CD8(+) T-Cells as Immune Regulators of Multiple Sclerosis ⬇️

scientific article

Characterization of human platelet binding of recombinant T cell receptor ligand.

scientific article

Detection of preceding Campylobacter jejuni infection by polymerase chain reaction in patients with Guillain-Barré syndrome.

scientific article

Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells.

scientific article

Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis

scientific article

IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis.

scientific article published on February 2008

Immune regulation of multiple sclerosis by CD8+ T cells

scientific article

Induction of regulatory T-cells from memory T-cells is perturbed during acute exacerbation of multiple sclerosis

scientific article published on 03 May 2016

Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis

scientific article published on 6 March 2013

RTL therapy for multiple sclerosis: a Phase I clinical study.

scientific article

RTL551 treatment of EAE reduces CD226 and T-bet+ CD4 T cells in periphery and prevents infiltration of T-bet+ IL-17, IFN-γ producing T cells into CNS

scientific article (publication date: 2011)

Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis

scientific article published on January 2008

Suppression of autoimmune demyelinating disease by preferential stimulation of CNS-specific CD8 T cells using Listeria-encoded neuroantigen.

scientific article

List of works by Sushmita Sinha

A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS.

Altered expression of SIRPγ on the T-cells of relapsing remitting multiple sclerosis and type 1 diabetes patients could potentiate effector responses from T-cells

An autoimmune disease risk SNP, rs2281808, in SIRPG is associated with reduced expression of SIRPγ and heightened effector state in human CD8 T-cells

Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.

CD8(+) T-Cells as Immune Regulators of Multiple Sclerosis ⬇️

Characterization of human platelet binding of recombinant T cell receptor ligand.

Detection of preceding Campylobacter jejuni infection by polymerase chain reaction in patients with Guillain-Barré syndrome.

Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells.

Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis

IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis.

Immune regulation of multiple sclerosis by CD8+ T cells

Induction of regulatory T-cells from memory T-cells is perturbed during acute exacerbation of multiple sclerosis

Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis

RTL therapy for multiple sclerosis: a Phase I clinical study.

RTL551 treatment of EAE reduces CD226 and T-bet+ CD4 T cells in periphery and prevents infiltration of T-bet+ IL-17, IFN-γ producing T cells into CNS

Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis

Suppression of autoimmune demyelinating disease by preferential stimulation of CNS-specific CD8 T cells using Listeria-encoded neuroantigen.